Neuropathic vs. inflammatory pain in chronic pancreatitis: can unique biomarkers be identified to guide mechanistic approaches to pain treatment?
慢性胰腺炎的神经性疼痛与炎性疼痛:是否可以确定独特的生物标志物来指导疼痛治疗的机制方法?
基本信息
- 批准号:9902440
- 负责人:
- 金额:$ 14.92万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-04-01 至 2024-01-31
- 项目状态:已结题
- 来源:
- 关键词:AbdomenAbdominal PainAffectAmylasesAnalgesicsAnimal ModelAnimalsBehaviorBiological AssayBiological MarkersBrain-Derived Neurotrophic FactorCellsCharacteristicsChronicClinicClinicalClinical ResearchDataDevelopmentDiagnosisEtiologyFoundationsFunctional disorderFutureGlucoseGoalsHistologyHumanImmuneInflammationInflammatoryInterleukin-1 betaKnowledgeLesionLinkLipaseMapsMeasuresMessenger RNAModelingMolecular TargetMorphologyNerve Growth FactorsNeurogenic InflammationNeuropathyNeuropeptidesNociceptionNon-Steroidal Anti-Inflammatory AgentsOpioidPainPain managementPancreasPancreatitisPatient MonitoringPatientsPatternPeripheralPeroxidasesPharmaceutical PreparationsPhenotypeQuality of lifeRegimenSamplingSerumSerum ProteinsSeveritiesSurveysSymptomsTestingTherapeuticTraininganimal model developmentanimal painbehavioral responsechronic pancreatitiscohortconditioned place preferencecytokinedesigndiagnosis designexperiencehuman datainflammatory markerinflammatory neuropathic paininflammatory painmouse modelnerve injurynew technologynoveloptogeneticspain signalpain symptompainful neuropathypatient biomarkersprospectiverecruitrelating to nervous systemtherapeutic evaluationtooltool development
项目摘要
Abstract
Chronic pancreatitis (CP) is often accompanied by profoundly debilitating pain that is quite difficult to treat.
There are no tools available in clinics to properly characterize the subtype of pain a patient is experiencing to
choose a therapy most likely to benefit a patient’s pain symptoms. There are two peripheral mechanisms that
could contribute, inflammatory pain (IP) and neuropathic pain (NP). A major driver of IP is neurogenic
inflammation, inflammation resulting from increased neural activity that drives release of neuropeptides that
recruit/activate immune cells. NP results from direct nerve injury (compression or lesion). Importantly, both
types of pain are accompanied by unique changes in cytokine expression that can be used to identify
mechanisms (IP and/or NP) contributing to a patient’s pain. The development of tools to differentiate IP and NP
in the clinic could ultimately streamline CP pain management because there is evidence that certain therapies
are far more efficacious for one type of pain versus the other. For example, opioids are more effective for IP
while gabapentinoids are more useful for NP. This proposal is designed to compare a novel animal model in
which pancreatitis pain is induced purely by IP (optogenetic) and a commonly used animal model of CP
(chronic cerulein) in which pain is a result of both IP and NP. The goal is to identify cytokine profiles associated
with the specific pain phenotypes and compare to legacy samples from a well-characterized clinical cohort of
CP patients. We will also test whether patients show correlations between cytokine profiles and pain
characteristics. The long-term plan is to use an iterative approach that uses patient data to refine animal
models of CP that can then be used to develop pain-type specific therapies.
In addition to incorporating new technologies (optogenetic) to the study of CP, this project will provide in depth
training in handling and analyzing human data and will provide a foundation for future prospective human
studies that will include survey tools specifically designed for diagnosis of inflammatory and neuropathic pain in
humans with CP.
抽象的
慢性胰腺炎(CP)通常伴随着非常衰弱的疼痛,这是相当差异的。
诊所没有可用的工具可以正确地表征患者的疼痛亚型是经验
选择最有可能使患者疼痛症状受益的疗法。
可能有助于炎症(IP)和神经性疼痛(NP)。
炎症,神经活性释放神经肽的炎症,炎症,神经肽的释放
募集/激活免疫细胞
疼痛的类型伴随着细胞因子表达的独特变化,可用于识别
机制(IP和或NP)有助于患者的疼痛。
在诊所诊所最终简化CP疼痛管理,因为某些疗法
例如,一种疼痛与另一种疼痛相比,阿片类药物更有效
尽管Gabapentinoids对NP更有用。
哪些胰腺炎疼痛纯粹是由IP(光遗传学)和CP的常用动物模型诱导的
(慢性Cerulein)疼痛是IP和NP的结果。
与特定的疼痛表型相比
CP患者。
特征。
然后可以使用CP模型来开发疼痛类型的特定疗法。
除了将新技术(光遗传学)纳入CP的研究外,该项目还深入
处理和分析人类数据的培训,并将为未来的潜在人类提供基础
研究将包括专门设计用于诊断炎症和神经性疼痛炎症的调查工具
人类与CP。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jami Lynn Saloman其他文献
Jami Lynn Saloman的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jami Lynn Saloman', 18)}}的其他基金
Biomarkers to stratify pain severity and type in pancreatic disease
用于对胰腺疾病疼痛严重程度和类型进行分层的生物标志物
- 批准号:
10707763 - 财政年份:2023
- 资助金额:
$ 14.92万 - 项目类别:
Mechanism-based Approach to Pain in Chronic Pancreatitis (MAP-CP Study)
基于机制的慢性胰腺炎疼痛治疗方法(MAP-CP 研究)
- 批准号:
10263243 - 财政年份:2020
- 资助金额:
$ 14.92万 - 项目类别:
Mechanism-based Approach to Pain in Chronic Pancreatitis (MAP-CP Study)
基于机制的慢性胰腺炎疼痛治疗方法(MAP-CP 研究)
- 批准号:
9976126 - 财政年份:2020
- 资助金额:
$ 14.92万 - 项目类别:
Neuropathic vs. inflammatory pain in chronic pancreatitis: can unique biomarkers be identified to guide mechanistic approaches to pain treatment?
慢性胰腺炎的神经性疼痛与炎性疼痛:是否可以确定独特的生物标志物来指导疼痛治疗的机制方法?
- 批准号:
10335169 - 财政年份:2019
- 资助金额:
$ 14.92万 - 项目类别:
Neuropathic vs. inflammatory pain in chronic pancreatitis: can unique biomarkers be identified to guide mechanistic approaches to pain treatment?
慢性胰腺炎的神经性疼痛与炎性疼痛:是否可以确定独特的生物标志物来指导疼痛治疗的机制方法?
- 批准号:
10555264 - 财政年份:2019
- 资助金额:
$ 14.92万 - 项目类别:
Neuropathic vs. inflammatory pain in chronic pancreatitis: can unique biomarkers be identified to guide mechanistic approaches to pain treatment?
慢性胰腺炎的神经性疼痛与炎性疼痛:是否可以确定独特的生物标志物来指导疼痛治疗的机制方法?
- 批准号:
10083736 - 财政年份:2019
- 资助金额:
$ 14.92万 - 项目类别:
Functional Interactions Between Peripheral P2X3 and TRP Channels
外设 P2X3 和 TRP 通道之间的功能交互
- 批准号:
8261843 - 财政年份:2011
- 资助金额:
$ 14.92万 - 项目类别:
Functional Interactions Between Peripheral P2X3 and TRP Channels
外设 P2X3 和 TRP 通道之间的功能交互
- 批准号:
8060323 - 财政年份:2011
- 资助金额:
$ 14.92万 - 项目类别:
相似国自然基金
肠易激综合征(IBS)腹痛的细胞和分子机制研究
- 批准号:81971046
- 批准年份:2019
- 资助金额:55 万元
- 项目类别:面上项目
中枢介导的腹痛综合征患者大脑多模态磁共振成像研究
- 批准号:81800482
- 批准年份:2018
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
疏肝健脾法通过调控组蛋白乙酰化修饰降低肝郁脾虚IBS-D内脏高敏感的机制研究
- 批准号:81703955
- 批准年份:2017
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
基于PKCγ/ERK1/2/MAPK信号通路探讨安肠汤缓解腹泻型肠易激综合征腹痛研究
- 批准号:81560754
- 批准年份:2015
- 资助金额:39.0 万元
- 项目类别:地区科学基金项目
针刺治疗功能性消化不良上腹痛综合征的疼痛记忆淡化机制研究
- 批准号:81473602
- 批准年份:2014
- 资助金额:73.0 万元
- 项目类别:面上项目
相似海外基金
MECHANISMS OF VISCERAL PAIN DRIVEN BY SMALL INTESTINAL MICROBIOTA
小肠微生物驱动内脏疼痛的机制
- 批准号:
10836298 - 财政年份:2023
- 资助金额:
$ 14.92万 - 项目类别:
Abdominal Pain in Older Patients in Emergency Departments
急诊科老年患者的腹痛
- 批准号:
10739136 - 财政年份:2023
- 资助金额:
$ 14.92万 - 项目类别:
Pharmacodynamics, Pharmacogenetics, Clinical Efficacy and Safety of Tradipitant for Functional Dyspepsia
Tradpitant 治疗功能性消化不良的药效学、药物遗传学、临床疗效和安全性
- 批准号:
10611491 - 财政年份:2022
- 资助金额:
$ 14.92万 - 项目类别:
Randomized controlled trial of an internet-based prevention intervention for young children at-risk for functional abdominal pain
针对有功能性腹痛风险的幼儿进行基于互联网的预防干预的随机对照试验
- 批准号:
10387725 - 财政年份:2022
- 资助金额:
$ 14.92万 - 项目类别:
Pharmacodynamics, Pharmacogenetics, Clinical Efficacy and Safety of Tradipitant for Functional Dyspepsia
Tradpitant 治疗功能性消化不良的药效学、药物遗传学、临床疗效和安全性
- 批准号:
10409418 - 财政年份:2022
- 资助金额:
$ 14.92万 - 项目类别: